

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

During the scoping process it was highlighted by the company that treatment of acanthamoeba keratitis is mainly provided by specialist centres. Therefore, there may be a delay in treatment dependent on location in England and ability to travel to access treatment.
--

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

The appraisal committee should consider this, but it is unlikely that the committee's recommendations would adversely affect people protected by the equality legislation.
--

- | |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No

Approved by Associate Director (name): Ross Dent

Date: 08/04/2025